Wire · technology
Tissue-specific cfDNA blood test maps organ toxicity to solve drug failure rates
◆ Sectors
Drug Discovery
◆ Source
◆ Verified
Fusion42 · 3 September 2026 · Fusion42 review
A new tissue-specific circulating free DNA (cfDNA) blood test allows mapping of organ toxicity, enabling earlier detection and intervention to reduce drug development failures.
This Wire brief sits within Fusion42's coverage of Drug Discovery.
◆ ◆ The Wire takeaway
Drug developers now have a blood test that spots organ toxicity early, cutting costly failures. You should explore integrating this to speed candidate validation and avoid late-stage project losses.
◆ Coverage
1 source · 3 Sep 2026
◆ Related on Wire
◆ Topics
Drug DiscoverycfDNAdrug-failuretoxicity-mappingblood-testdrug-development